

## Release of Restricted Securities

**Microba Life Sciences Limited** (ASX: MAP) ("Microba" or the "Company"), advises in accordance with ASX Listing Rule 3.10A, that the following securities, which were subject to voluntary escrow as part of the Company's acquisition of Invivo Clinical Limited in December 2023 will be released from escrow as follows:

- **13,141,578 fully paid ordinary shares will be released from escrow on 6 December 2025.**

The release of these securities does not affect the Company's total issued capital.

*This announcement has been authorised for release by the Chair and CEO.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

**Investor / Media Relations**

[investor@microba.com](mailto:investor@microba.com)

<https://ir.microba.com/welcome>

**About Microba Life Sciences Limited**

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that helps people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. [www.microba.com](http://www.microba.com)



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](http://ir.microba.com/welcome)

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621